$32.4m market cap

$0.15 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and ClyraGuard, a disinfectant for healthcare workers. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo stated that it expects Clyra Medical (of which it owns a 48% interest) and its Clyraguard product to be a major driver of growth in the coming periods. Clyra Medical signed an agreement with a major national distributor in July, with the first substantial sales to occur in Q320. Clyra Medical reported a small revenue ($21,000) for Q220, reflecting one week of sales from a previous test marketing run.

Register to receive research on BioLargo as it is published
Share price graph
Price performance
Actual 2.5 (30.7) (57.7)
Relative* (2.1) (34.3) (63.0)
52-week high/low US$0.3/US$0.1
*% relative to local index
Key management
Dennis Calvert President & CEO